ArticleHuman vaccines & immunotherapeutics2026
Predictors of initiation and completion of Shingrix vaccination in immunocompetent adults newly eligible for vaccination from 2018-2024.
Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Shingrix vaccine has been recommended for immunocompetent adults aged ≥50 y since October 2017. It is important to assess recent trends and predictors of Shingrix vaccination among those newly eligible to evaluate acceptability, desirability, and uptake of the vaccine. In this retrospective cohort study, we used electronic health record data with linked medical and pharmacy claims data from Truveta. Immunocompetent adults turning 50 between 2018 and 2024 with at least 1 y of continuous enrollment after their 50th birthday were included. We estimated the cumulative incidence of vaccination by eligibility year and assessed series completion at 6 and 12 m. Multivariable logistic regression identified predictors of initiation and series completion. Among 153,899 adults (57.0% female; 62.2% White), 9.9% received ≥1 Shingrix dose within 1 y of eligibility. One-year uptake increased from 2.6% (2018 cohort) to 14.0% (2024 cohort). Three-year uptake reached 27.5% among those eligible in 2022. Among initiators within the first year of eligibility, 62.6% completed the series within 6 m and 74.5% within 12 m. Influenza vaccination during a person's 50th y was the strongest non time-based predictor of Shingrix vaccination (odds ratio 1.96, 95% CI 1.88-2.03). Women and Asian adults had higher odds of initiation, whereas Black or African American adults, Medicaid/CHIP enrollees, rural residents, and those with cardiovascular disease had lower odds. Shingrix uptake among newly eligible adults has increased rapidly since 2018. Persistent sociodemographic disparities highlight the need for targeted strategies to improve equitable vaccine uptake.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.